MIRA PHARMACEUTICALS: Leadership & Compensation Changes Reported
Ticker: MIRA · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
TL;DR
**MIRA PHARMACEUTICALS just reported leadership and compensation changes, watch for details.**
AI Summary
MIRA PHARMACEUTICALS, INC. filed an 8-K on January 17, 2024, reporting an event that occurred on January 15, 2024, related to changes in directors or officers and their compensation. This filing indicates potential shifts in leadership or executive compensation structures, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for details on who departed or was appointed, and the specifics of any new compensatory arrangements, as these changes can influence future performance and stock valuation.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial adjustments, directly influencing investor confidence and the company's operational stability.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership and compensation without specific details, creating uncertainty about future company direction and stability.
Analyst Insight
A smart investor would await further detailed disclosures regarding the specific individuals involved in the leadership changes and the terms of any new compensatory arrangements to assess the potential impact on the company's future strategy and financial health.
Key Players & Entities
- MIRA PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- January 15, 2024 (date) — date of the earliest event reported
- January 17, 2024 (date) — date the 8-K was filed
- 001-41765 (number) — Commission File Number for MIRA PHARMACEUTICALS, INC.
- $0.0001 (dollar_amount) — par value per share of Common Stock
FAQ
What specific event did MIRA PHARMACEUTICALS, INC. report in this 8-K filing?
MIRA PHARMACEUTICALS, INC. reported an event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per Item 5.02 of Form 8-K.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 15, 2024.
What is the Commission File Number for MIRA PHARMACEUTICALS, INC.?
The Commission File Number for MIRA PHARMACEUTICALS, INC. is 001-41765.
What is the par value per share of MIRA PHARMACEUTICALS, INC.'s Common Stock?
The par value per share of MIRA PHARMACEUTICALS, INC.'s Common Stock is $0.0001.
What is the business address of MIRA PHARMACEUTICALS, INC. as stated in the filing?
The business address of MIRA PHARMACEUTICALS, INC. is 855 N Wolfe Street, Suite 601, Baltimore, Maryland, 21205.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2024-01-17 16:30:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-002729.txt ( ) — 210KB
- mira-20240115.xsd (EX-101.SCH) — 3KB
- mira-20240115_lab.xml (EX-101.LAB) — 33KB
- mira-20240115_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Date, January 17, 2024 By: /s/ Michelle Yanez Michelle Yanez Chief Financial Officer